Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CHENEAU, Caroline
POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer	Active, not recruiting	3	405	Europe	Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy	ETOP IBCSG Partners Foundation, Pfizer	Breast Cancer Recurrent	01/26	01/29
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)	Recruiting	3	300	Europe	Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT	UNICANCER, Bayer	Prostate Cancer Metastatic	03/28	09/37

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CHENEAU, Caroline
POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer	Active, not recruiting	3	405	Europe	Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy	ETOP IBCSG Partners Foundation, Pfizer	Breast Cancer Recurrent	01/26	01/29
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)	Recruiting	3	300	Europe	Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT	UNICANCER, Bayer	Prostate Cancer Metastatic	03/28	09/37